Tech Company Financing Transactions
Aquestive Therapeutics Funding Round
On 8/14/2025, Aquestive Therapeutics raised $75 million in funding from RTW Investments.
Transaction Overview
Company Name
Announced On
8/14/2025
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Undisclosed
Investors
RTW Investments (Roderick Wong)
Proceeds Purpose
This financing provides critical capital that will support Aquestive Therapeutics through 2027, enabling us to successfully bring Anaphylm to market, if approved by the FDA, and deliver a new treatment option for patients in need.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30 Technology Drive
Warren, NJ 07059
USA
Warren, NJ 07059
USA
Phone
Undisclosed
Website
Email Address
Overview
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Barber
Browse more venture capital transactions:
Prev: 8/14/2025: Topline Pro venture capital transaction
Next: 8/14/2025: Studio Atelico venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs